Tobacco-Based Covid Vaccine May Start Clinical Trials in Weeks

July 31, 2020, 8:15 AM

An experimental Covid-19 vaccine that’s produced in tobacco plants may start clinical trials within weeks as the race for immunization intensifies.

British American Tobacco Plc, the maker of Lucky Strike cigarettes, expects a response from the U.S. Food and Drug Administration any day now, Chief Marketing Officer Kingsley Wheaton said in an interview.

“We’re optimistic,” Wheaton said. “It’s an important part of our strategy to try and build a better tomorrow.”

Tobacco makers, whose products are linked to lung damage, have been jumping into the race to develop a vaccine against the coronavirus, a pandemic that’s mainly spread by...

To read the full article log in.

Learn more about a Bloomberg Law subscription.